Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Visiongain Report Offers Transformative Insights on $47bn Rheumatoid Arthritis Market

      Visiongain Logo (PRNewsfoto/Visiongain)

      News provided by

      Visiongain

      Jan 11, 2019, 05:00 ET

      Share this article

      Share this article


      LONDON, January 11, 2019 /PRNewswire/ --

      Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029 

      Biologics, Non-Biologics, NSAIDs, sDMARDs and Others 

      The global rheumatoid arthritis drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis Drugs market.

           (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

      How this report will benefit you
      Read on to discover how you can exploit the future business opportunities emerging in this sector.

      In this brand new 232-page report you will receive 234 charts- all unavailable elsewhere.

      The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

      By ordering and reading our brand-new report today you stay better informed and ready to act.

      Report Scope 

      • Global Rheumatoid Arthritis Market from 2019-2029 

      • Forecast of the Global Rheumatoid Arthritis market by Submarket:
      • Biologics
      • Non-Biologics: NSAIDs, sDMARDs and Others

      • Forecast of the leading drugs in the Global Rheumatoid Arthritis market:
      • Humira
      • Enbrel
      • Remicade
      • Rituxan/MabThera
      • Simponi/Simponi Aria
      • Orencia
      • Actemra/Roactemra
      • Cimzia
      • Celebrex
      • Xeljanz
      • Arcoxia
      • Others

      • This report provides individual revenue forecasts to 2029 for these regional and national markets:
      • North America: US, Canada
      • Europe: Germany, France, United Kingdom, Italy, Spain, Russia and rest of Europe
      • Asia-Pacific: Japan, China, India and rest of Asia-Pacific
      • Latin America: Brazil, Mexico, Rest of Latin America
      • Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

      Each regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

      • Our study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:
      • AbbVie
      • Amgen
      • AstraZeneca
      • BMS
      • Eli Lilly
      • Johnson & Johnson
      • Merck & Co
      • Novartis
      • Pfizer
      • Roche
      • Sanofi
      • UCB

      • Our study discusses selected compounds under development for rheumatoid arthritis.

      • This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.

      Visiongain's study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.

      Buy our report today Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

      To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2019-2029/

      Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.

      Abbvie
      Ablynx
      Abott Laboratories
      Alder
      Amgen
      Astellas Pharma Inc.
      Baxalta
      Biocad
      Biocon Limited
      Biogen Inc.
      Bioxpress Therapeutics
      BMS
      Boehringer Ingelheim
      Bristol-Myers Squibb Company
      Cadila Healthcare
      Can-Fite
      Celtrion
      Chugai Pharmaceutical Co Ltd.
      Cipla
      Coherus BioSciences Inc
      Covagen AG
      Daiichi Sankyo
      Dermira, Inc.
      Dr Reddy's Laboratories
      Eli Lilly
      Epirus Biopharmaceuticals
      F. Hoffmann-La Roche Ltd (Roche)
      Fujifilm Corporation
      Fujifilm Kyowa Kirin
      Galapagos NV
      Genentech
      Gerresheimer
      Gilead Sciences Inc
      GlaxoSmithKline plc
      Hanmi Pharmaceutical
      Hanwha Chemical
      Hetero Group
      Hospira
      IMS Health
      Incyte Corporation
      Intas Pharmaceuticals Limited
      Janseen Biologics
      Johnson and Johnson
      LG Life Sciences
      Lycera Corporation
      Merck KGaA
      Mitsubishi
      Momenta Pharmaceuticals
      MorphoSys
      Mycenax Biotech Inc.
      Mylan N.V.
      Nichi-Iko Pharmaceutical
      Novartis
      Novo Nordisk
      Oncobiologics
      Padlock
      Pfenex
      Pfizer
      Protalix Biotherapeutics
      Regeneron Pharmaceuticals, Inc.
      Roche
      Samsung Bioepis
      Sanofi S.A.
      Shanghai Celgen
      Shanghai CP Goujian Pharmaceutical Co
      Sharp & Dhome
      Simcere Pharmaceuticals
      Sun Pharma
      Takeda Pharmaceuticals
      Tanabe Pharma
      Torrent Pharmaceuticals
      TSH Biopharm
      UCB
      Van der Heijde
      Vitaeris
      Zydus Cadila

      Other Organizations Mentioned in This Report
      African League of Associations in Rheumatology
      American College of Rheumatology
      ANVISA (Agência Nacional de Vigilância Sanitária)
      Arthritis Foundation
      Bumrungrad
      Canadian Arthritis Society
      Centers for Disease Control and Prevention (CDC)
      Cleveland Clinic
      Committee for Medicinal Products for Human Use (CHMP)
      Emirates Arthritis Foundation
      European Commission
      European Medicines Agency
      Government of Abu Dhabi
      Institut fϋr Qualität und Wirtschaftlichkeit im Gesundheitswesen - IQWiG
      Institute for Quality and Efficiency in Healthcare
      International League of Associations for Rheumatology
      Johns Hopkins
      Ministry of Health
      National Center for Biotechnology Information
      National Institute for Health and Care Excellence (NICE)
      National Institute for Health Research (NIHR)
      National Institute on Aging
      National Rheumatoid Arthritis Society
      National Treasury of Republic of South Africa
      Nurses Health
      Servizio Sanitario Nazionale (SSN)
      U.S. Food and Drug Administration (FDA)
      Unified Health System
      United Nations
      US Patent Office
      Vamed
      WHO
      World Arthritis Day
      World Bank

      To see a report overview please e-mail Sara Peerun on [email protected]

      SOURCE Visiongain

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.